Neuroprotection in Parkinson's disease

Parkinsonism & Related Disorders
Anthony H V Schapira

Abstract

A major focus in Parkinson's disease (PD) research is to produce drugs or other interventions that can slow or stop clinical progression. This should include an effect on both motor and non-motor symptoms and so target dopaminergic and non-dopaminergic pathways. It is logical to assume that the best chance of developing such therapies will be based on forming a better understanding of the aetiology and pathogenesis of PD and to identify critical molecular targets. There have been great advances in finding different genetic causes and risk factors for PD, but less so in the discovery of environmental contributions. The separate genetic causes still share common pathways to cell dysfunction and death, and these interconnect at several levels. Despite the major advances in genetics and PD pathogenesis, we still do not have good models of PD that can be used with confidence to accurately predict the effect of drugs on disease progression. Clinical trial design and study population selection are also areas that represent significant challenges to testing any putative neuro-protective agent. Several drugs have attracted attention as potential neuroprotective agents in PD. There are numerous studies demonstrating beneficial effects in...Continue Reading

References

Mar 1, 1990·Journal of Neurochemistry·A H SchapiraC D Marsden
Jun 1, 1988·Journal of Bioenergetics and Biomembranes·J A Morgan-HughesJ B Clark
May 24, 1995·Biochimica Et Biophysica Acta·J A Morgan-HughesJ B Clark
Oct 1, 1993·The Quarterly Journal of Medicine·P R SmithA H Schapira
Jun 15, 1996·Annals of the New York Academy of Sciences·A D OwenC D Marsden
May 5, 1998·Journal of Hepatology·A A MorrisA H Schapira
Oct 31, 1998·Brain Research·T A SeatonA H Schapira
Jan 29, 1999·BMJ : British Medical Journal·A H Schapira
Feb 3, 1999·JAMA : the Journal of the American Medical Association·C M TannerJ W Langston
Apr 1, 2003·Annals of Neurology·Thomas T Warner, Anthony H V Schapira
Nov 1, 2003·Science·A B SingletonK Gwinn-Hardy
May 26, 2004·Lancet Neurology·Anthony H V Schapira
Nov 10, 2004·Archives of Neurology·Michelangelo MancusoSalvatore DiMauro
Feb 21, 2006·Lancet Neurology·K Ray ChaudhuriUNKNOWN National Institute for Clinical Excellence
Feb 21, 2006·Annals of Neurology·Anthony H V Schapira, Jose Obeso
May 24, 2006·Neurology·Anthony H V Schapira
Jul 4, 2006·Lancet·Anthony H V Schapira
Oct 4, 2006·Nature Reviews. Drug Discovery·Anthony H V SchapiraGiora Davidai
Dec 21, 2007·Lancet Neurology·Anthony H V Schapira
Dec 29, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Julia FuchsThomas Gasser
Jan 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Angela C PooleLeo J Pallanck
Apr 11, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira
Apr 11, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira
Apr 9, 2008·Nature Medicine·Jeffrey H KordowerC Warren Olanow
Jun 10, 2008·Lancet Neurology·Daniel G HealyUNKNOWN International LRRK2 Consortium
Sep 19, 2008·Proceedings of the National Academy of Sciences of the United States of America·Hansong DengMing Guo
Nov 26, 2008·The Journal of Cell Biology·Derek NarendraRichard J Youle
Dec 2, 2008·Trends in Pharmacological Sciences·Anthony H V Schapira
Jan 2, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Robert G HartJohn R Marler
Apr 21, 2009·Lancet Neurology·K Ray Chaudhuri, Anthony H V Schapira
May 15, 2009·Brain : a Journal of Neurology·Laura FlinnOliver Bandmann
Jun 27, 2009·Neurologic Clinics·Anthony H V Schapira
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Paula DesplatsSeung-Jae Lee
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·C Warren Olanow, Stanley B Prusiner
Aug 18, 2009·Nature Neuroscience·Luke S TainAlexander J Whitworth
Sep 3, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H SchapiraE Tolosa
Sep 25, 2009·The New England Journal of Medicine·C Warren OlanowUNKNOWN ADAGIO Study Investigators
Sep 13, 2013·Annals of Neurology·Laura J FlinnOliver Bandmann

❮ Previous
Next ❯

Citations

Jun 25, 2016·International Journal of Molecular Sciences·Sumit SarkarSyed Imam
Dec 30, 2015·Brain Research·Nicole D Osier, C Edward Dixon
Apr 10, 2017·Journal of Neural Transmission·Marc Morissette, Thérèse Di Paolo
Apr 5, 2018·Frontiers in Neurology·Liyan HouQingshan Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.